- In November 2024, PathAI, has integrated AI products from top companies like Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight1 Image Management System (IMS). This collaboration enhances AISight's versatility, reliability, and interoperability, allowing PathAI to offer a more comprehensive and seamless solution, strengthening its position in the market
- In November 2024, Deep Bio has partnered with PathAI to integrate its DeepDx Prostate solution for prostate cancer analysis with PathAI's AISight1 Image Management System (IMS). This collaboration combines Deep Bio's AI technology with PathAI's platform, enhancing access to advanced diagnostic tools for prostate cancer, and strengthening both companies' positions in the digital pathology market
- In November 2024, Aiforia and Paige have formed a non-exclusive partnership to integrate Paige’s Diagnostic AI applications into the Aiforia Platform, enhancing functionality and performance. This collaboration will improve laboratory efficiency, diagnostic accuracy, and patient care, helping both companies deliver advanced AI-powered solutions to their customers. This partnership strengthens their market presence and offers more comprehensive diagnostic tools
- In November 2024, Royal Philips expanded its strategic collaboration with Amazon Web Services (AWS) to offer its integrated diagnostics portfolio, including radiology, digital pathology, cardiology, and AI solutions, in the cloud. This collaboration will streamline diagnostic workflows, enhance access to critical insights, and improve clinical outcomes, further strengthening Philips’ position in the healthcare technology market
- In June 2024, Quest Diagnostics completed its acquisition of PathAI Diagnostics to accelerate the adoption of AI and digital pathology in cancer and disease diagnosis. This acquisition will enhance Quest's diagnostic capabilities, enabling more accurate and efficient disease detection through advanced AI technologies
- In February 2024, F. Hoffmann-La Roche Ltd entered into an exclusive agreement with PathAI to develop AI-enabled digital pathology algorithms for companion diagnostics through Roche Tissue Diagnostics (RTD). While RTD will collaborate solely with PathAI on these algorithms, it retains the ability to develop its own in-house algorithms. This partnership will enhance Roche’s diagnostic capabilities and accelerate the development of personalized treatments through advanced AI-powered solutions
